UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of ~~earliest~~Earliest ~~event~~Event ~~reported~~Reported): March 9, 2010

November 10, 2009

AUTOIMMUNE INC.

(Exact Name of Registrant as specified in its charter)

DELAWARE

0-20948

13-348-9062

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1199 Madia Street, Pasadena, CA		91103
(Address of Principal Executive Offices)		(Zip Code)

1199 Madia Street, Pasadena, CA 91103

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (626) 792-1235

Not Applicable

(Registrant’s name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-d2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e.-4 (c))

Item 2 8.~~02.~~01 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On March 9, 2010, AutoImmune Inc. (the “Company”) issued a press release onannouncing ~~November 10,~~that ~~2009~~its ~~announcing~~Board ~~its~~of ~~financial~~Directors ~~results~~has ~~for~~approved ~~the~~a ~~quarter~~Plan ~~ended~~of ~~September 30~~Complete Liquidation and Dissolution of the Company, subject ~~2009~~to stockholder approval, and has filed a Form 15 with the Securities and Exchange Commission to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934. A copy of ~~which~~the ispress ~~furnished~~release is attached as Exhibit 99.1 ~~hereto~~to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 2.02 and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not applicable

(b) Pro Forma Financial Information.

Not applicable

(d) Exhibits.

~~Exhibit~~ 99.1 Press Release dated ~~November 10~~March 9, ~~2009~~2010.

~~SIGNATURES~~SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~thereunto duly authorized.

Date: November 12, 2009	AUTOIMMUNE INC.
	By:	/S/ DIANE M. MCCLINTOCK
	Name:	Diane M. McClintock
	Title:	Director of Finance and Treasurer


AUTOIMMUNE INC.

By:		/s/ Diane M. McClintock
		Diane M. McClintock
		Director of Finance and Treasurer

Date: March 9, 2010

Filing Compare · AUTOIMMUNE INC